Welcome to chemicalbook!
Chinese English Japanese Germany Korea
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Encorafenib (LGX818)

Encorafenib (LGX818) synthesis

14synthesis methods
Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. Synthetic Description Reference: Huang, Shenlin; Jin, Xianming; Liu, Zuosheng; Poon, Daniel; Tellew, John; Wan, Yongqin; Wang, Xing; Xie, Yongping. Preparation of sulfonamidophenylimidazolylpyrimidine derivatives and analogs for use as protein kinase inhibitors. Assignee IRM LLC, Bermuda; Novartis A.-G. WO 2011025927. (2011).
Synthetic Routes
  • ROUTE 1
  • 202112074784711213.jpg

    Reference: Huang, Shenlin; Jin, Xianming; Liu, Zuosheng; Poon, Daniel; Tellew, John; Wan, Yongqin; Wang, Xing; Xie, Yongping. Preparation of sulfonamidophenylimidazolylpyrimidine derivatives and analogs for use as protein kinase inhibitors. Assignee IRM LLC, Bermuda; Novartis A.-G. WO 2011025927. (2011).

202112074784711213.jpg

Reference: Huang, Shenlin; Jin, Xianming; Liu, Zuosheng; Poon, Daniel; Tellew, John; Wan, Yongqin; Wang, Xing; Xie, Yongping. Preparation of sulfonamidophenylimidazolylpyrimidine derivatives and analogs for use as protein kinase inhibitors. Assignee IRM LLC, Bermuda; Novartis A.-G. WO 2011025927. (2011).

1996-30-1 Synthesis
2-Bromo-4-chloro-1-fluorobenzene

1996-30-1
217 suppliers
$5.00/1g

-

Yield:-

Steps:

Multi-step reaction with 7 steps
1.1: lithium diisopropyl amide / tetrahydrofuran / 1 h / -78 °C
1.2: -78 - 20 °C
2.1: diphenylphosphoranyl azide; triethylamine / toluene / 2 h / 75 - 84 °C
2.2: 0.25 h / 35 °C
3.1: dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate / 1,4-dioxane / 16 h / 100 °C
4.1: sodium carbonate / tetrakis(triphenylphosphine) palladium(0) / ethanol; water; toluene / 16 h / 80 °C
5.1: trifluoroacetic acid / dichloromethane / 1 h / 20 °C
6.1: triethylamine / 2-methyltetrahydrofuran / -5 - 20 °C
6.2: pH 6 - 6.5
6.3: 0.17 h / 20 °C / pH 7 - 7.5
7.1: sodium hydroxide / 2-methyltetrahydrofuran; water / 0.5 h / 20 - 23 °C
7.2: pH 6 - 6.5
7.3: pH 8.5

References:

IRM LLC;NOVARTIS AG;HUANG, Shenlin;JIN, Xianming;LIU, Zuosheng;POON, Daniel;TELLEW, John;WAN, Yongqin;WANG, Xing;XIE, Yongping WO2011/25927, 2011, A1

Encorafenib (LGX818) Related Search: